Inclusion Criteria:

- Patients ≥18 years with selected metastatic solid tumours recognized to be highly
vascularised and not amenable to any clinical improvement by current standard
treatments

- Colorectal cancer (CRC) patients previously resistant to standard systemic
regimens (including biologic agents)

- Gastric cancer (GC) patients treated with no more than two standard systemic
regimens for metastatic disease

- Hepatocellular carcinoma (HCC) patients previously resistant to standard
systemic regimens

- Pancreatic carcinoma (PC) patients treated with no more than one standard
systemic regimen for metastatic disease

- Non small cell lung carcinoma (NSCLC) patients treated with no more than two
standard systemic regimens (including biologic agents) for metastatic disease

- Neuroendocrine (NE) tumours refractory to somatostatin analogue treatment

- Other rare tumours including malignant pleural mesothelioma (MPM), soft-tissue
sarcoma (STS), and renal cell carcinoma (RCC), resistant/refractory to current
standard treatments

- Life expectancy more than 3 months

- ECOG Performance status 0-1

- Adequate baseline bone marrow, hepatic and renal function, defined as follows:

- Neutrophils >1.5 x 10^9/L and platelets > 100 x 10^9/L

- Bilirubin <1.5 x ULN

- AST and/or ALT <2.5 x ULN in absence of liver metastasis

- AST and/or ALT <5 x ULN in presence of liver metastasis

- Serum creatinine <1.5 x ULN

- Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50
ml/min

- Patients may have had prior therapy providing the following conditions are met before
treatment start:

- Chemotherapy, radiation therapy, hormonal therapy, or immunotherapy: wash-out
period of 28 days

- Surgery: wash-out period of 14 days

- Patients must give written informed consent to participate in the study.

Exclusion Criteria:

- Concurrent anticancer therapy

- Patients must not receive any other investigational agents while on study

- Patients with myocardial infarction within the last six (6) months, unstable angina,
New York Heart Association (NYHA) grade II or greater congestive heart failure, or
serious cardiac arrhythmia requiring medication

- Uncontrolled hypertension

- Prolonged QTc interval (congenital or acquired) > 450 ms

- Patient with significant peripheral vascular disease

- History or evidence upon physical examination of CNS disease unless adequately
treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with
standard medical therapy), or history of stroke

- Patients with active or uncontrolled systemic disease/infections or with serious
illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction or contraindications to human albumin
preparations or to any of the excipients

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol

- Pregnancy or lactation. Patients - both males and females - with reproductive
potential (i.e. menopausal for less than 1-year and not surgically sterilized) must
practice effective contraceptive measures throughout the study. Women of
child-bearing potential must provide a negative pregnancy test (serum or urine)
within 14 days prior to registration.